EntryPoint Capital LLC Invests $244,000 in Omnicell, Inc. (NASDAQ:OMCL)

EntryPoint Capital LLC purchased a new stake in shares of Omnicell, Inc. (NASDAQ:OMCL) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 5,487 shares of the company’s stock, valued at approximately $244,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in OMCL. Vanguard Group Inc. lifted its position in Omnicell by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 5,562,165 shares of the company’s stock valued at $247,628,000 after buying an additional 28,573 shares during the period. Victory Capital Management Inc. lifted its position in Omnicell by 32.9% during the 4th quarter. Victory Capital Management Inc. now owns 1,526,309 shares of the company’s stock valued at $67,951,000 after acquiring an additional 377,883 shares during the period. Sumitomo Mitsui Trust Group Inc. boosted its stake in Omnicell by 93.3% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,450,416 shares of the company’s stock worth $64,573,000 after acquiring an additional 699,925 shares in the last quarter. ArrowMark Colorado Holdings LLC grew its holdings in Omnicell by 27.1% in the third quarter. ArrowMark Colorado Holdings LLC now owns 1,140,873 shares of the company’s stock worth $49,742,000 after purchasing an additional 243,353 shares during the period. Finally, Geode Capital Management LLC increased its stake in shares of Omnicell by 0.3% during the third quarter. Geode Capital Management LLC now owns 1,104,745 shares of the company’s stock valued at $48,176,000 after purchasing an additional 2,877 shares in the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

OMCL has been the topic of a number of analyst reports. JPMorgan Chase & Co. dropped their price target on Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a research report on Thursday, March 20th. Bank of America cut their target price on Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a research note on Monday, January 6th. Wells Fargo & Company lowered their price target on Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Benchmark reiterated a “buy” rating and issued a $62.00 price target on shares of Omnicell in a research note on Tuesday, February 4th. Finally, StockNews.com lowered shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Monday, March 24th. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $51.00.

Omnicell Stock Performance

Shares of OMCL stock opened at $35.01 on Friday. The firm has a market capitalization of $1.64 billion, a PE ratio of 129.67, a P/E/G ratio of 7.53 and a beta of 0.85. The company has a 50 day moving average price of $39.01 and a 200-day moving average price of $42.58. Omnicell, Inc. has a 52 week low of $25.12 and a 52 week high of $55.75. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. As a group, equities research analysts expect that Omnicell, Inc. will post 1.09 earnings per share for the current year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.